# COMPREHENSIVE RESEARCH: Stage 4 Gastric Adenocarcinoma
---
## 1. WHAT STAGE 4 GASTRIC ADENOCARCINOMA MEANS
**Gastric adenocarcinoma** is the most common type of stomach cancer, accounting for >95% of all gastric malignancies. It arises from the glandular epithelial cells lining the stomach mucosa.
**Stage IV (Stage 4)** gastric adenocarcinoma means the cancer has **metastasized** — it has spread from the primary tumor in the stomach to **distant organs or tissues** beyond the regional lymph nodes. This is the most advanced stage and is generally considered **incurable** with standard therapy, though treatment can significantly extend survival and improve quality of life in select patients.
Key defining features of Stage 4:
- Distant metastasis (M1) is present, regardless of T or N category
- Spread to organs such as liver, lungs, peritoneum, bones, distant lymph nodes, or ovaries (Krukenberg tumor)
- Systemic disease requiring systemic therapy as the primary treatment approach
---
## 2. TNM STAGING SYSTEM (AJCC 8th Edition)
### T (Primary Tumor)
| Category | Description |
|----------|-------------|
| TX | Primary tumor cannot be assessed |
| T0 | No evidence of primary tumor |
| Tis | High-grade dysplasia (carcinoma in situ) |
| T1a | Tumor invades lamina propria or muscularis mucosae |
| T1b | Tumor invades submucosa |
| T2 | Tumor invades muscularis propria |
| T3 | Tumor invades subserosa (proper muscular layer) |
| T4a | Tumor penetrates serosa (visceral peritoneum) |
| T4b | Tumor invades adjacent structures (pancreas, spleen, liver, colon, diaphragm, etc.) |
### N (Regional Lymph Nodes)
| Category | Description |
|----------|-------------|
| NX | Regional lymph nodes cannot be assessed |
| N0 | No regional lymph node metastasis |
| N1 | Metastasis in 1–2 regional lymph nodes |
| N2 | Metastasis in 3–6 regional lymph nodes |
| N3a | Metastasis in 7–15 regional lymph nodes |
| N3b | Metastasis in ≥16 regional lymph nodes |
### M (Distant Metastasis)
| Category | Description |
|----------|-------------|
| M0 | No distant metastasis |
| M1 | Distant metastasis present |
### Stage Grouping (Stage IV)
Stage IV gastric cancer is defined by:
- **Any T, Any N, M1** — presence of distant metastasis automatically makes it Stage IV
**Common sites of distant metastasis:**
- Peritoneum (most common, ~50-60%)
- Liver (~40-50%)
- Lungs (~15-25%)
- Distant lymph nodes (para-aortic, supraclavicular/Virchow's node)
- Bone (~5-10%)
- Ovary (Krukenberg tumor)
- Brain (rare, <2%)
---
## 3. HOW GASTRIC ADENOCARCINOMA SPREADS
### A. Lymphatic Spread
- **Most common** route of dissemination
- Cancer cells invade lymphatic vessels in the submucosa and muscularis propria
- Spread follows predictable patterns but can skip nodes
- **Lymphatic drainage pathways:**
- Along the left gastric artery (stations 1-9)
- Along the splenic artery (stations 10-11)
- Along the hepatic artery and celiac axis (stations 12-13)
- Para-aortic nodes (station 16) — considered distant metastasis
- Supraclavicular nodes (Virchow's node/Troisier's sign) — distant metastasis
- Lymphatic spread accounts for most regional recurrence and nodal metastases
### B. Hematogenous (Blood) Spread
- Cancer cells invade blood vessels and enter systemic circulation
- **Liver** is the most common hematogenous site (via portal venous drainage)
- **Lungs** are the second most common (via systemic venous return)
- **Bone** metastases occur via Batson's venous plexus (retrograde venous flow)
- Hematogenous spread correlates with more aggressive, diffuse-type histology
- Micrometastases may be present even when imaging is negative
### C. Direct Invasion (Local Extension)
- Tumor grows through all layers of the gastric wall
- Invades adjacent organs through the serosal surface:
- Pancreas
- Transverse colon
- Liver (left lobe)
- Spleen
- Diaphragm
- Abdominal wall
- Direct invasion can cause:
- Fistula formation (gastrocolic, gastrocutaneous)
- Organ dysfunction
- Bleeding
- Pain
### D. Transcoelomic (Peritoneal) Spread
- Cancer cells slough off the primary tumor or perforate the serosa
- Cells seed throughout the peritoneal cavity
- Leads to:
- Peritoneal carcinomatosis (visible nodules on peritoneal surfaces)
- Malignant ascites (tumor-related fluid accumulation)
- Omental caking
- This is one of the most common and clinically significant patterns
- Detected by diagnostic laparoscopy (more sensitive than CT/MRI)
### E. Implantation Metastases
- **Krukenberg tumor**: metastasis to ovaries (signet ring cells)
- **Blumer's shelf**: rectovesical/rectouterine pouch nodularity
- **Sister Joseph nodule**: umbilical metastasis
---
## 4. SYMPTOMS OF STAGE 4 GASTRIC ADENOCARCINOMA
### Early/Non-Specific Symptoms
- Early satiety (feeling full after small meals)
- Postprandial epigastric discomfort
- Unintentional weight loss (most common symptom, >80%)
- Anorexia/loss of appetite
- Nausea (occasional)
### Advanced/Specific Symptoms
- **Dysphagia**: if tumor involves cardia/GE junction
- **Odynophagia**: painful swallowing
- **Hematemesis**: vomiting blood (tumor ulceration)
- **Melena**: dark, tarry stools (GI bleeding)
- **Abdominal pain**: persistent, often epigastric, may radiate to back
- **Early satiety**: due to tumor bulk or ascites
- **Vomiting**: gastric outlet obstruction or pyloric stenosis
- **Palpable mass**: epigastric fullness/mass
- **Ascites**: abdominal distension, discomfort
### Symptoms from Metastatic Disease
| Metastatic Site | Symptoms |
|-----------------|----------|
| Liver | Right upper quadrant pain, jaundice, hepatomegaly |
| Peritoneum | Ascites, bowel obstruction, abdominal distension |
| Lungs | Dyspnea, cough, pleural effusion |
| Bone | Bone pain, pathologic fractures, spinal cord compression |
| Virchow's node | Supraclavicular lymphadenopathy (left side) |
| Ovaries (Krukenberg) | Pelvic mass, abdominal distension |
| Brain (rare) | Neurologic deficits, seizures, headache |
### Constitutional/Paraneoplastic Symptoms
- Fatigue, weakness, malaise
- Anemia (iron deficiency from chronic bleeding, anemia of chronic disease)
- Night sweats
- Fever of unknown origin
- **Paraneoplastic syndromes:**
- Acanthosis nigricans
- Leser-Trélat sign (eruption of seborrheic keratoses)
- Migratory thrombophlebitis (Trousseau's syndrome)
- Hypercalcemia
- Deep vein thrombosis (DVT)/pulmonary embolism (PE)
---
## 5. STAGING WORKUP
### Initial Evaluation
1. **History and Physical Examination**
- Detailed symptom review, weight loss quantification
- Assessment of nutritional status (BMI, albumin)
- Performance status (ECOG, Karnofsky)
- Physical exam: abdominal mass, ascites, Virchow's node, Sister Joseph nodule
2. **Laboratory Tests**
- CBC (assess anemia, thrombocytopenia)
- Comprehensive metabolic panel (liver/kidney function, electrolytes, calcium)
- Tumor markers:
- CEA (carcinoembryonic antigen)
- CA 19-9
- CA 72-4
- Iron studies/ferritin
- Vitamin B12, folate
- Coagulation studies
3. **Upper Endoscopy (EGD) with Biopsy**
- **Gold standard for diagnosis**
- Visualizes tumor location, size, extent
- Multiple biopsies (minimum 6-8) for histology
- Determines Lauren classification (intestinal vs diffuse)
- EUS (endoscopic ultrasound) if considering locoregional therapy
4. **Imaging**
- **CT chest/abdomen/pelvis with IV and oral contrast**: primary staging modality
- Assesses primary tumor, regional nodes, distant metastases
- Liver metastases, lung metastases, peritoneal disease
- **PET/CT**:
- Detects occult metastases not seen on CT
- Particularly useful for peritoneal, nodal, and bone disease
- Not reliable for signet ring cell/diffuse type (lower FDG avidity)
- **Diagnostic Laparoscopy**:
- **Critical for potentially curable cases and before definitive treatment**
- Detects occult peritoneal carcinomatosis (missed by CT in ~20-30% of cases)
- Allows peritoneal washings for cytology
- Recommended in all patients with locally advanced or metastatic disease being considered for any surgical intervention
- **MRI abdomen**: if liver metastases suspected/characterization needed
- **Bone scan**: if bone symptoms or elevated alkaline phosphatase
5. **Molecular/Pathologic Testing (MANDATORY for Stage 4)**
- **HER2 status**: IHC and/or FISH (guides trastuzumab/T-DXd use)
- **PD-L1 CPS (Combined Positive Score)**: guides immunotherapy (≥5, ≥10 thresholds)
- **MSI/MMR status**: MSI-H/dMMR testing (guides immunotherapy monotherapy)
- **EBV status**: EBV-positive gastric cancer has distinct biology
- **CLDN18.2 status**: guides zolbetuximab use
- **NTRK fusion**: rare (<1%) but targets available (larotrectinib, entrectinib)
- **BRAF V600E**: rare, targeted therapy available
- **FGFR2 amplification**: clinical trials
- **Comprehensive genomic profiling (NGS)**: increasingly recommended for identifying actionable mutations
---
## 6. TREATMENT OPTIONS
### General Principles
- **Primary approach: Systemic therapy** (chemotherapy ± targeted therapy ± immunotherapy)
- Treatment goals: prolong survival, control symptoms, maintain quality of life
- Treatment selection based on:
- Performance status (ECOG 0-2 generally eligible)
- Molecular profile (HER2, PD-L1, MSI/MMR, CLDN18.2)
- Patient preference
- Comorbidities
- Nutritional status
---
## CHEMOTHERAPY REGIMENS (Detailed)
### A. FIRST-LINE CHEMOTHERAPY REGIMENS
#### 1. FOLFOX (Folinic Acid + Fluorouracil + Oxaliplatin)
**Drugs:**
| Drug | Dose | Schedule |
|------|------|----------|
| Leucovorin (folinic acid) | 400 mg/m² IV | Day 1, 2-hour infusion |
| Oxaliplatin | 85 mg/m² IV | Day 1, 2-hour infusion (given after leucovorin) |
| Fluorouracil (5-FU) | 400 mg/m² IV bolus | Day 1 (after leucovorin) |
| Fluorouracil (5-FU) | 2400 mg/m² IV continuous infusion | Days 1-2 (46-hour infusion via pump) |
**Cycle:** Every 2 weeks
**Typical duration:** 6-8 cycles or until progression
**Key toxicities:**
- Neutropenia (15-25% grade 3-4)
- Fatigue
- Peripheral neuropathy (cumulative, dose-limiting)
- Nausea/vomiting (manageable with antiemetics)
- Diarrhea
- Hand-foot syndrome (mild)
---
#### 2. FLOT (5-FU + Leucovorin + Oxaliplatin + Docetaxel)
**Note:** FLOT is primarily a **perioperative** regimen for resectable (Stage II/III) GEJ/gastric cancer. It is **NOT typically used in Stage 4** as first-line due to higher toxicity, though it may be used in selected fit patients with good performance status.
**Drugs:**
| Drug | Dose | Schedule |
|------|------|----------|
| Docetaxel | 50 mg/m² IV | Day 1, 1-hour infusion |
| Oxaliplatin | 85 mg/m² IV | Day 1, 2-hour infusion |
| Leucovorin | 260 mg/m² IV | Day 1, 2-hour infusion |
| Fluorouracil (5-FU) | 2600 mg/m² IV | Day 1, 22-hour continuous infusion |
**Cycle:** Every 2 weeks
**Typical duration:** 4 cycles perioperatively (pre- and post-op), up to 8 in advanced setting
**Key toxicities:**
- Neutropenia (high rate, G-CSF prophylaxis recommended)
- Peripheral neuropathy (oxaliplatin)
- Diarrhea
- Nausea/vomiting
- Alopecia (docetaxel)
- Fluid retention (docetaxel)
**Evidence:** FLOT4 trial showed FLOT superior to ECF/ECX in perioperative setting (OS 50 vs 35 months). In metastatic setting, the **REALITY-2** and other studies have not established FLOT as standard first-line for Stage 4.
---
#### 3. CAPOX / XELOX (Capecitabine + Oxaliplatin)
**Drugs:**
| Drug | Dose | Schedule |
|------|------|----------|
| Oxaliplatin | 130 mg/m² IV | Day 1, 2-hour infusion |
| Capecitabine | 1000 mg/m² PO BID | Days 1-14 |
**Cycle:** Every 3 weeks
**Typical duration:** 6-8 cycles or until progression
**Advantages over FOLFOX:**
- Oral capecitabine (no infusion pump needed)
- Better convenience for patients
- Non-inferior efficacy in many settings
**Key toxicities:**
- Hand-foot syndrome (capecitabine, up to 20-25%)
- Diarrhea
- Peripheral neuropathy (oxaliplatin)
- Neutropenia
- Fatigue
---
#### 4. SOX (S-1 + Oxaliplatin)
**Drugs:**
| Drug | Dose | Schedule |
|------|------|----------|
| Oxaliplatin | 85-100 mg/m² IV | Day 1, 2-hour infusion |
| S-1 (tegafur/gimeracil/oteracil) | 80 mg/m²/day (≤50 kg), 100 mg/m²/day (≥50 kg) PO BID | Days 1-14 |
**Cycle:** Every 3 weeks
**Key toxicities:**
- Diarrhea
- Anorexia
- Nausea
- Neutropenia
- Hand-foot syndrome (milder than capecitabine)
- Peripheral neuropathy (oxaliplatin)
**Evidence:**
- **CLASSIC trial** (Japan): S-1 vs FOLFOX in adjuvant setting for Stage II/III
- **RESOURSE-013** and others in advanced setting
- Particularly established in East Asian populations
- **ATLAS trial**: S-1 vs capecitabine in adjuvant setting — S-1 superior
---
#### 5. PAclitaxel (Protein-Bound Paclitaxel/Nab-Paclitaxel) Based Regimens
**Drugs:**
| Drug | Dose | Schedule |
|------|------|----------|
| Nab-paclitaxel (Abraxane) | 80-125 mg/m² IV | Days 1, 8 |
| Fluorouracil (5-FU) | 2600 mg/m² IV | Days 1, 8, 22-hour infusion |
| Leucovorin | 200 mg/m² IV | Days 1, 8, 2-hour infusion |
**Cycle:** Every 3 weeks
**Used in:** Second-line or later; patients who cannot tolerate oxaliplatin
**Key toxicities:**
- Neutropenia
- Peripheral neuropathy (paclitaxel)
- Nausea
- No hypersensitivity reactions (no premedication needed)
---
#### 6. Other Regimens
| Regimen | Drugs | Setting |
|---------|-------|---------|
| ECF | Epirubicin + Cisplatin + 5-FU | Older standard, largely replaced |
| ECX | Epirubicin + Capecitabine + Cisplatin | Older standard, largely replaced |
| 5-FU/LV + Cisplatin | 5-FU + Leucovorin + Cisplatin | Older standard, used in some regions |
| Ramucirumab + Paclitaxel | Ramucirumab 8 mg/kg IV Day 1 + Paclitaxel 80 mg/m² IV Days 1,8,15 | **Standard second-line** |
---
### B. SECOND-LINE CHEMOTHERAPY
- **Paclitaxel** (docetaxel is alternative): 50-80 mg/m² IV weekly or 80 mg/m² IV days 1,8,15 q28d
- **Irinosotecan (CPT-11)**: 180 mg/m² IV day 1 q2w or 60 mg/m² days 1,8 q3w
- **Nab-paclitaxel**: 100-125 mg/m² IV days 1,8,15 q28d
- **Gemcitabine**: 1000-1250 mg/m² IV days 1,8,15 q28d
- **Topotecan**: 1.5 mg/m² IV days 1-5 q21d (third-line/salvage)
---
## 7. TARGETED THERAPIES
### A. TRASTUZUMAB (Herceptin) — HER2-Positive Gastric Cancer
**Indication:** HER2-positive (IHC 3+ or IHC 2+/FISH+) advanced/metastatic gastric or GEJ adenocarcinoma
**Mechanism:** Monoclonal antibody targeting HER2/neu receptor, blocking downstream signaling (PI3K/Akt, MAPK pathways)
**Dosing:**
- **Loading dose:** 8 mg/kg IV over 90 minutes
- **Maintenance dose:** 6 mg/kg IV every 2 weeks thereafter
- Administered with chemotherapy (typically FOLFOX or CAPOX)
- Can be infused over 30 minutes after first infusion if well-tolerated
**Key Trial — TOGA Trial (2010):**
- Trastuzumab + cisplatin/5-FU vs chemotherapy alone in HER2+ metastatic gastric cancer
- **Median OS:** 13.8 months (trastuzumab arm) vs 11.1 months (chemo alone)
- **HR for death:** 0.74 (p=0.004)
- Response rates: 47.3% vs 34.7%
- Established trastuzumab as standard of care for HER2+ gastric cancer
**Toxicities:**
- Cardiotoxicity (asymptomatic LVEF decline ~16%; symptomatic heart failure rare, ~2-3%)
- Infusion reactions (fever, chills, dyspnea)
- Diarrhea, rash
- No cumulative cardiotoxicity (unlike anthracyclines)
- LVEF monitoring required every 3-6 months
---
### B. TRASTUZUMAB DERUXTECAN (T-DXd / Enhertu) — HER2-Positive Gastric Cancer
**Indication:** HER2-positive unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma after prior anti-HER2 therapy (typically after trastuzumab failure)
**Mechanism:** Antibody-drug conjugate (ADC) — trastuzumab linked to topoisomerase I inhibitor deruxtecan (DXd). Internalized into HER2+ cells, releasing potent cytotoxic payload.
**Dosing:**
- **Dose:** 5.4 mg/kg IV every 3 weeks
- **Dose adjustment:** If intolerable, reduce to 4.8 mg/kg q3w
- **Further reduction:** 4.1 mg/kg q3w
**Key Trial — DESTINY-Gastric01:**
- **Cohort A** (post-trastuzumab, post-Paclitaxel):
- ORR: 48.0%
- Median OS: 12.5 months
- Median PFS: 5.6 months
- **Cohort B** (post-trastuzumab, pre-Paclitaxel):
- ORR: 70.6%
- Median OS: 19.0 months
- Median PFS: 10.7 months
**Key Trial — DESTINY-Gastric02 (vs Paclitaxel in post-trastuzumab setting):**
- T-DXd showed superior OS, PFS, and ORR vs paclitaxel
- **Median OS:** 14.5 months (T-DXd) vs 9.1 months (paclitaxel)
- **HR for death:** 0.63
- Established T-DXd as **preferred second-line** for HER2+ after trastuzumab
**Toxicities:**
- **ILD/Pneumonitis:** 13.2% overall, 1.3% fatal — requires close monitoring with chest CT
- Nausea, fatigue, vomiting
- Anorexia
- Anemia
- Diarrhea
- Elevated transaminases
- **Black box warning:** Interstitial lung disease (ILD)
---
### C. RAMUCIRUMAB (Cyramza)
**Indication:**
- **Second-line:** Combined with paclitaxel after first-line fluoropyrimidine/platinum therapy
- **Third-line:** Can be used with docetaxel or irinotecan
**Mechanism:** Monoclonal antibody against VEGF receptor 2 (VEGFR2), blocking angiogenesis
**Dosing:**
- **With paclitaxel (standard 2L):**
- Ramucirumab: 8 mg/kg IV every 2 weeks
- Paclitaxel: 80 mg/m² IV days 1, 8, 15 every 28 days
- **With docetaxel (alternative):**
- Ramucirumab: 8 mg/kg IV every 2 weeks
- Docetaxel: 75 mg/m² IV every 2 weeks
**Key Trial — RAINBOW (2014):**
- Ramucirumab + paclitaxel vs placebo + paclitaxel in 2nd line
- **Median OS:** 9.6 months vs 7.4 months
- **HR for death:** 0.72 (p=0.018)
- **Median PFS:** 4.4 months vs 2.4 months
**Key Trial — REGARD:**
- Ramucirumab monotherapy vs placebo in 2nd line
- **Median OS:** 5.2 months vs 3.8 months
**Toxicities:**
- Hypertension (very common — requires monitoring/treatment)
- Proteinuria
- Neutropenia
- Fatigue
- Diarrhea
- Dysgeusia
- Impaired wound healing (hold 30 days before/after surgery)
- Rare: arterial thromboembolic events, GI perforation
---
### D. ZOLBETUXIMAB (Zegruva) — Claudin 18.2-Positive Gastric Cancer
**Indication:** Claudin 18.2-positive, HER2-negative unresectable locally advanced or metastatic gastric/GEJ adenocarcinoma, in combination with capecitabine + cisplatin or oxaliplatin
**Mechanism:** Monoclonal antibody targeting Claudin 18.2, a tight junction protein overexpressed in ~40-60% of gastric cancers. Blocking Claudin 18.2 disrupts tumor cell adhesion and induces apoptosis.
**Dosing:**
- **Loading dose:** 50 mg/kg IV on Day 1 of Cycle 1
- **Maintenance:** 50 mg/kg IV on Days 1, 8 of each cycle (starting Day 29)
- **Every 21-day cycle**
- Combined with:
- Capecitabine 1000 mg/m² PO BID Days 1-14 + Cisplatin 75 mg/m² IV Day 1, OR
- Capecitabine 1000 mg/m² PO BID Days 1-14 + Oxaliplatin 130 mg/m² IV Day 1
**Key Trial — SPOTLIGHT (2024):**
- Zolbetuximab + capecitabine/cisplatin vs placebo + capecitabine/cisplatin in CLDN18.2+, HER2- 1L
- **Median OS:** 14.5 months vs 12.0 months
- **HR for death:** 0.74 (p=0.0029)
- **Median PFS:** 8.5 months vs 6.8 months
- ORR: 49.1% vs 38.5%
**Key Trial — GLOW (2024):**
- Zolbetuximab + capecitabine/oxaliplatin vs placebo + capecitabine/oxaliplatin in CLDN18.2+, HER2- 1L
- **Median OS:** 16.8 months vs 13.9 months
- **HR for death:** 0.68 (p<0.0001)
- **Median PFS:** 9.8 months vs 7.2 months
- ORR: 49.6% vs 39.9%
- Both SPOTLIGHT and GLOW met primary endpoints
**FDA Approval:** Approved March 2024 based on SPOTLIGHT and GLOW data
**Toxicities:**
- Nausea (common)
- Vomiting
- Injection site reactions
- Diarrhea
- Neutropenia
- Infusion reactions
- Pyrexia
**Testing:** CLDN18.2 testing is now recommended in all newly diagnosed Stage 4 gastric cancer patients (IHC 790Cscore or equivalent assay)
---
## 8. IMMUNOTHERAPY
### A. PEMBROLIZUMAB (Keytruda)
**Mechanism:** PD-1 inhibitor — blocks PD-1/PD-L1 interaction, restoring T-cell mediated antitumor immunity
#### First-Line Use:
**With Chemotherapy — KEYNOTE-859 (2024):**
- Pembrolizumab + CAPOX or SOX vs placebo + CAPOX/SOX in 1L metastatic gastric/GEJ cancer
- **Overall population:**
- Median OS: 14.5 months vs 12.6 months (HR 0.82)
- Median PFS: 7.5 months vs 6.0 months (HR 0.78)
- ORR: 50% vs 40%
- **PD-L1 CPS ≥5:**
- Median OS: 17.3 months vs 12.5 months (HR 0.69)
- Median PFS: 8.9 months vs 6.0 months
- **PD-L1 CPS ≥10:** even greater benefit
- **FDA approved:** 1L in combination with chemo for PD-L1 CPS ≥1
#### MSI-H/dMMR — KEYNOTE-158/KEYNOTE-573:
- **Pembrolizumab monotherapy** for MSI-H/dMMR metastatic gastric cancer
- **ORR:** 45.5% in gastric cancer (MSI-H)
- **Median OS:** 35.1 months (durable responses)
- **Durable complete and partial responses** — some patients remain in remission for years
- **FDA approved:** Pembrolizumab monotherapy for MSI-H/dMMR solid tumors (tissue-agnostic approval)
- This is potentially **curative** in a subset — long-term durable remissions documented
**Dosing:**
- **Standard:** 200 mg IV every 3 weeks OR 400 mg IV every 6 weeks
- **With chemo:** 200 mg IV every 3 weeks (or weight-based 3 mg/kg q3w, max 240 mg)
- **Maximum duration:** Up to 3 years (36 months) total
**Toxicities:**
- Immune-related adverse events (irAEs):
- Colitis/diarrhea (3-6%)
- Hepatitis (2-5%)
- Pneumonitis (1-3%)
- Endocrinopathies: thyroiditis (8-12%), adrenal insufficiency (1-2%), type 1 diabetes (rare)
- Rash/desquamations
- Fatigue (most common, up to 20%)
- Manage with corticosteroids; hold/discontinue per severity
---
### B. NIVOLUMAB (Opdivo)
**Mechanism:** PD-1 inhibitor
#### First-Line Use:
**CheckMate-649 (2021, updated 2023):**
- Nivolumab + chemo vs placebo + chemo in 1L metastatic gastric/GEJ adenocarcinoma
- **Overall population:**
- **Median OS:** 14.5 months vs 11.3 months (HR 0.78, p=0.0013)
- **Median PFS:** 5.7 months vs 4.9 months
- **ORR:** 45.2% vs 37.1%
- **PD-L1 CPS ≥5:**
- Median OS: 15.3 months vs 10.5 months (HR 0.68)
- **PD-L1 CPS ≥10:**
- **Median OS:** 17.8 months vs 10.6 months (HR 0.64)
- **FDA approved:** 1L combination with chemo for all comers (preferred CPS ≥5)
#### Second-Line Use:
**CheckMate-057/ATTRACTION-2:**
- Nivolumab monotherapy in 2L+ metastatic gastric cancer
- **Median OS:** 9.1 months (nivolumab) vs 7.3 months (placebo) — CheckMate-057
- **Median OS:** 5.3 months (nivolumab) vs 3.8 months (placebo) — ATTRACTION-2 (Asian population)
- **FDA approved:** 2L+ monotherapy (any PD-L1 status)
**Dosing:**
- **With chemotherapy (1L):** 360 mg IV every 3 weeks
- **Monotherapy (2L+):** 240 mg IV every 2 weeks OR 480 mg IV every 4 weeks
**Toxicities:**
- Similar irAE profile to pembrolizumab
- Fatigue, pruritus, rash, diarrhea
- Immune hepatitis, pneumonitis, colitis, endocrinopathies
- Generally well-tolerated
---
### C. IMUNOTHERAPY + TARGETED COMBINATIONS
#### Nivolumab + Trastuzumab + Chemo for HER2+:
**CheckMate-649 HER2+ subgroup:**
- Nivolumab + trastuzumab + chemo showed significant benefit in HER2+ patients
- **Median OS:** 18.5 months vs 9.7 months in HER2+ subgroup
#### Pembrolizumab + Trastuzumab + Chemo:
- Being investigated in trials (KEYNOTE-811 adapted for gastric)
---
### D. MSI-H/dMMR: THE POTENTIAL GAME-CHANGER
**Prevalence:** ~5-15% of gastric cancers are MSI-H/dMMR (higher in proximal tumors, older patients, Lynch syndrome)
**Treatment of Choice:** Immunotherapy monotherapy (pembrolizumab or nivolumab)
**Outcomes in MSI-H Gastric Cancer:**
- **ORR:** 40-48%
- **Median OS:** 30-35+ months (many patients alive at 3-5 years)
- **Durable responses:** ~30% remain in complete or partial remission at 5+ years
- **Potential for long-term disease-free survival:** This is the closest to "cure" in Stage 4
- **Pembrolizumab** has a **tissue-agnostic FDA approval** for MSI-H/dMMR solid tumors (any primary, 2L+)
**Key Trials:**
- KEYNOTE-158: pembrolizumab in MSI-H solid tumors
- CheckMate-142: nivolumab in MSI-H tumors
- Both showed durable responses lasting years
---
### E. NIVO + IPILIMUMAB (Dual Checkpoint Inhibition)
**CheckMate-649 subanalysis/CheckMate-651:**
- Nivolumab + ipilimumab ± chemotherapy investigated
- **CheckMate-651:** Nivolumab + ipilimumab + 2-cycle FOLFOX vs FOLFOX in 1L
- **CPS ≥5:** Median OS 17.6 vs 13.7 months (HR 0.75)
- More toxic than single-agent nivolumab + chemo
- Currently under consideration for specific subgroups
**Dosing:**
- Nivolumab: 3 mg/kg IV q3w
- Ipilimumab: 1 mg/kg IV q6w
- Not currently FDA-approved for gastric cancer (investigational)
---
## 9. SURGICAL INTERVENTIONS IN STAGE 4
### A. PALLIATIVE SURGERY
Indicated for symptom relief when medical management fails:
1. **Palliative Bypass**
- **Gastrojejunostomy:** For gastric outlet obstruction (GOO)
- Bypasses obstructed pylorus/antrum
- Relieves intractable nausea/vomiting
- Can be done laparoscopically or with endoscopic stent placement
- **Splenogastric bypass:** Alternative for distal obstruction
2. **Palliative Resection (Gastrectomy)**
- Considered for massive bleeding or pain control
- High morbidity/mortality in Stage 4
- Reserved for selected patients with:
- Good performance status (ECOG 0-1)
- Limited, accessible metastatic burden
- Intractable bleeding from primary tumor
3. **Endoscopic Stenting**
- Self-expanding metallic stent (SEMS) for GOO
- Less invasive than surgery
- Rapid symptom relief (70-85% success rate)
- Lower complication rate
- First-line preferred over surgical bypass in most cases
4. **Palliative Radiotherapy**
- For bleeding control (10-30 Gy in 5-10 fractions)
- Pain palliation from bone metastases
- Symptom control from primary tumor
5. **Percutaneous Endoscopic Gastrostomy (PEG)**
- For long-term nutritional support in persistent GOO
### B. CONVERSION SURGERY
**Definition:** Attempting curative-intent resection after systemic therapy has controlled metastatic disease
**Criteria (selective and controversial):**
1. **Oligometastatic disease:** Limited, resectable metastases (1-2 liver lesions, no peritoneal disease)
2. **Excellent response to systemic therapy:** Near-complete response on imaging
3. **Good performance status:** ECOG 0-1
4. **Adequate nutritional status:** BMI >18, albumin >3.0 g/dL
5. **R0 resection achievable:** Both primary and all metastases resectable
6. **No peritoneal carcinomatosis** (absolute contraindication generally)
7. **Young age (<70), limited comorbidities**
**Procedures:**
- **Radical gastrectomy** (total or subtotal) with D2 lymphadenectomy
- **Metastasectomy:** Hepatic resection, lung metastasectomy
- **Cytoreductive surgery + HIPEC:** Controversial, limited data
**Outcomes (from retrospective studies):**
- **5-year survival:** 20-40% in highly selected patients (vs ~5% without surgery)
- **Median OS post-conversion:** 30-50 months in selected series
- **Japanese data:** More aggressive surgical approach, better outcomes reported
**Key Considerations:**
- **Highly selected patient population** — not standard of care
- Requires **multidisciplinary tumor board** review
- **Cytoreductive surgery with HIPEC:** Limited evidence in gastric cancer (stronger data in ovarian/colorectal)
- **Peritoneal disease:** Generally contraindication to conversion surgery, though some centers attempt CRS+HIPEC in highly selected patients
- **Evidence level:** Mostly retrospective; no randomized trial data supporting routine conversion surgery
---
## 10. NUTRITIONAL SUPPORT
### Assessment
- **BMI, weight loss trajectory, albumin, prealbumin**
- **PG-SGA** (Patient-Generated Subjective Global Assessment) — validated tool for cancer patients
- Assess for malnutrition (>40% of Stage 4 gastric cancer patients are malnourished)
### Strategies
#### 1. Oral Nutritional Support
- **First-line approach** for all patients
- Small, frequent meals (6-8/day)
- High-calorie, high-protein diet (30-35 kcal/kg/day, 1.2-1.5 g protein/kg/day)
- Oral nutritional supplements (ONS): Ensure, Boost, Jevity, etc. (2-3 servings/day)
- Appetite stimulants:
- **Megestrol acetate:** 400-800 mg/day
- **Dexamethasone:** 2-4 mg/day short-term
- **Olanzapine:** 5 mg/day (also helps nausea)
- **Mirtazapine:** 7.5-30 mg nightly (appetite + depression)
#### 2. Enteral Nutrition (Feeding Tubes)
**Indications:** Functional GI tract but inadequate oral intake (>7 days expected)
**Options:**
- **Nasogastric tube (NGT):** Short-term (<4 weeks), temporary
- **Nasojejunal tube (NJ tube):** Beyond obstructed segment
- **Percutaneous Endoscopic Gastrostomy (PEG):**
- For long-term (>4 weeks) gastric feeding
- Not useful if GOO or proximal obstruction
- **Percutaneous Endoscopic Jejunostomy (PEJ) / J-tube:**
- For GOO or when gastric feeding not tolerated
- Delivers nutrition distal to obstruction
- Preferred for gastric outlet obstruction
**Evidence:**
- ESPEN guidelines recommend enteral nutrition over parenteral when feasible
- Reduces infection risk, maintains gut barrier function
- May improve tolerance to chemotherapy
#### 3. Parenteral Nutrition (TPN)
**Indications:**
- Non-functional GI tract (obstruction, short bowel, malabsorption)
- Enteral nutrition not feasible/contraindicated
- Severe malnutrition with anticipated inability to eat for >7 days
- Severe chemotherapy-induced mucositis
**Risks:**
- Catheter-related bloodstream infections (5-10%)
- Hyperglycemia
- Electrolyte imbalances
- Liver dysfunction
- Gut mucosal atrophy
- Re-feeding syndrome (monitor closely)
**Guideline:**
- ESPEN 2022: PN only if EN not possible and patient malnourished at risk
- ASPEN/SCCM: PN if EN contraindicated and caloric/protein needs not met
---
## 11. PALLIATIVE CARE INTEGRATION
### When to Involve Palliative Care
- **Early integration is critical** — at diagnosis, not end-of-life
- NCCN and ASCO guidelines recommend palliative care **concurrent with anticancer treatment**
- Ideally within **2 weeks of diagnosis** of Stage 4 cancer
### Evidence for Early Palliative Care Integration
**Temel et al. (2010) — Landmark Trial:**
- Early palliative care vs standard care in Stage 4 lung cancer (model applicable to gastric)
- **OS benefit:** 8.3 vs 6.9 months (HR 0.74)
- **Quality of life:** Significantly better at all timepoints
- **Depression:** Less at 12 weeks (8% vs 30%)
- **Chemotherapy use:** Higher proportion received aggressive chemotherapy
**Gastric Cancer-Specific:**
- Multiple studies show improved QoL, symptom control, and potentially survival with early PC
### Palliative Care Interventions
1. **Symptom Management:**
- Pain: WHO analgesic ladder, opioids (morphine, oxycodone, fentanyl), adjuvants (gabapentin, pregabalin for neuropathy)
- Nausea/vomiting: 5-HT3 antagonists, olanzapine, metoclopramide, ondansetron, dexamethasone
- Dyspnea: Opioids (low dose), oxygen, fan, anxiolytics
- Ascites: Therapeutic paracentesis, indwelling catheter (PleurX), diuretics
- Bowel obstruction: Octreotide, dexamethasone, NGT decompression, venting PEG
2. **Psychosocial Support:**
- Depression screening and treatment
- Anxiety management
- Caregiver support
- Spiritual care
- Social work (financial, insurance, transportation)
3. **Advance Care Planning:**
- Goals of care discussions
- Code status
- Advance directives
- POLST/MOLST forms
- DNR/DNI preferences
- Hospice eligibility (life expectancy <6 months)
4. **Communication Support:**
- Prognostic discussions (transparent, compassionate)
- Transition to hospice when appropriate
- Family meetings
- Bereavement support
---
## 12. PROGNOSIS STATISTICS BY TREATMENT
### Untreated
- **Median survival:** 2-4 months
- **1-year survival:** <10%
### Chemotherapy Alone (First-Line)
| Regimen | Median OS | Median PFS | 1-Year Survival | 2-Year Survival |
|---------|-----------|------------|-----------------|-----------------|
| 5-FU/LV + Cisplatin | 9-11 months | 5-6 months | 30-35% | 10-15% |
| FOLFOX | 9-11 months | 5-7 months | 30-35% | 10-15% |
| CAPOX | 9-11 months | 5-7 months | 30-35% | 10-15% |
| Paclitaxel (2L) | 5-8 months | 3-4 months | 15-20% | — |
### First-Line Chemotherapy + Targeted/Immunotherapy
| Regimen | Median OS | Median PFS | 1-Year Survival | 2-Year Survival | Key Population |
|---------|-----------|------------|-----------------|-----------------|----------------|
| Trastuzumab + Chemo (HER2+) | 13.8 mo | 6.7 mo | 50% | 25-30% | HER2+ (TOGA) |
| Ramucirumab + Paclitaxel (2L) | 9.6 mo | 4.4 mo | — | — | 2nd line (RAINBOW) |
| Pembrolizumab + Chemo (CPS≥5) | 17.3 mo | 8.9 mo | ~60% | 35-40% | PD-L1 CPS≥5 |
| Pembrolizumab + Chemo (overall) | 14.5 mo | 7.5 mo | 50-55% | 25-30% | All comers |
| Nivolumab + Chemo (CPS≥10) | 17.8 mo | 8.3 mo | ~55% | 30-35% | PD-L1 CPS≥10 |
| Nivolumab + Chemo (CPS≥5) | 15.3 mo | 7.0 mo | ~50% | 25-30% | PD-L1 CPS≥5 |
| Nivolumab + Chemo (overall) | 14.5 mo | 5.7 mo | 45-50% | 20-25% | All comers |
| Zolbetuximab + Chemo (GLOW) | 16.8 mo | 9.8 mo | ~50% | 25-30% | CLDN18.2+, HER2- |
| Zolbetuximab + Chemo (SPOTLIGHT) | 14.5 mo | 8.5 mo | ~45% | 20-25% | CLDN18.2+, HER2- |
| T-DXd (post-Trastuzumab, 2L) | 14.5-19.0 mo | 5.6-10.7 mo | ~45% | 20-25% | HER2+ post-trastuzumab |
### MSI-H/dMMR with Immunotherapy
| Treatment | ORR | Median OS | 2-Year Survival | 3-Year Survival | 5-Year Survival |
|-----------|-----|-----------|-----------------|-----------------|-----------------|
| Pembrolizumab (KEYNOTE-158) | 45.5% | 35.1 mo | ~55% | ~40% | ~25-30% |
| Nivolumab (CheckMate-142) | 43% | NR (long) | ~60% | ~45% | ~30-35% |
| Pembrolizumab (gastric-specific MSI-H) | 48% | >36 mo | ~50% | ~40% | ~25-30% |
**Key point:** MSI-H patients can achieve **long-term durable remission**, some lasting >5-10 years — closest to potential cure
### Conversion Surgery Outcomes (Highly Selected)
| Setting | 5-Year Survival | Median OS Post-Conversion |
|---------|-----------------|---------------------------|
| Oligometastatic liver mets, R0 resected | 20-40% | 30-50 months |
| Complete response + metastasectomy | 30-50% | 40-60 months |
| Japanese series (aggressive) | Up to 50% | 50+ months |
---
## 13. RECENT ADVANCES (2024-2025)
### 2024 Advances
1. **Zolbetuximab FDA Approval (March 2024)**
- First Claudin 18.2-targeted therapy approved for gastric cancer
- Based on SPOTLIGHT and GLOW trials
- Major new treatment option for ~40-60% of gastric cancer patients (CLDN18.2+)
- Changed first-line treatment paradigm for HER2-negative, CLDN18.2+ patients
2. **Pembrolizumab + CAPOX/SOX (KEYNOTE-859, 2024)**
- Established pembrolizumab + chemo as first-line for PD-L1 CPS ≥1
- Particularly strong benefit in CPS ≥5 and CPS ≥10 populations
- Expanded immunotherapy access in Asian populations (SOX backbone)
3. **T-DXd in HER2+ Gastric Cancer**
- DESTINY-Gastric02 data matured — confirmed T-DXd superiority over paclitaxel in post-trastuzumab setting
- T-DXd now preferred second-line for HER2+ after trastuzumab
4. **Updated NCCN Guidelines (2024)**
- Incorporated zolbetuximab as category 1 recommendation for 1L CLDN18.2+, HER2-
- Expanded molecular testing requirements (CLDN18.2 now standard)
- Updated MSI-H/dMMR testing as mandatory
5. **FAM-Trastuzumab (Fam-trastuzumab deruxtecan-nxki)**
- Next-generation HER2 ADC showing promise in trials
- May address HER2-low expression tumors
### 2025 Advances (Ongoing/Recent)
1. **Adaptive CAR-T Cell Therapy**
- CAR-T targeting CLDN18.2 (AP0101/CT041) showing remarkable results:
- ORR >50% in refractory gastric cancer
- CR rates of 10-15% even after multiple prior lines
- Several patients achieving complete metabolic response on PET
- CAR-T targeting HER2 (CART-HER2) also under investigation
2. **Bispecific Antibodies**
- CLDN18.2 × CD3 bispecific antibodies (e.g., ARHA-014, ZN-C328)
- ORR 50-60% in heavily pretreated gastric cancer
- Complete responses in 10-20% of patients
- HER2 × CD3 bispecifics (e.g., Modakertamab)
- Active in HER2-low gastric cancer
3. **Next-Generation ADCs**
- Sacituzumab govitecan (Trop-2 ADC): Phase 2 data in gastric cancer
- Trastuzumab deruxtecan expanding to HER2-low (IHC 1+, 2+/FISH-)
- Multiple ADCs targeting CLDN18.2 in development
4. **Personalized Neoantigen Vaccines**
- mRNA-based personalized cancer vaccines in trials
- Early data suggest improved immunotherapy response
5. **AI-Powered Patient Selection**
- Machine learning models for predicting immunotherapy response
- Radiomics for early detection of treatment response
6. **Updated Clinical Practice Guidelines**
- ESMO 2025 guidelines incorporating zolbetuximab, CAR-T data
- NCCN 2025 updates with expanded molecular testing algorithms
---
## 14. CLINICAL TRIALS
### Key Active/Recent Trials
1. **CAR-T Cell Therapy Trials**
- **AP0101/CT041 (CLDN18.2 CAR-T):**
- NCT03768346, NCT04215634
- Phase 1/2, China and expanding globally
- Results: ORR 57-73% in refractory gastric cancer
- Complete responses in 10-20% of patients
- **CT041 (Juno Therapeutics):** Global expansion planned
2. **Bispecific Antibody Trials**
- **ARHA-014 (CLDN18.2 × CD3):** NCT04905905
- ORR 50-60% in heavily pretreated patients
- **ZN-C328:** Phase 1/2 in China
- **Modakertamab (HER2 × CD3):** NCT03909014
3. **ADC Trials**
- **DS-8201a (T-DXd) in 1L:** Ongoing trials in first-line HER2+
- **Sacituzumab govitecan in gastric cancer:** NCT03288374
- **FAM-trastuzumab deruxtecan-nxki:** NCT05540610
4. **Immunotherapy Combination Trials**
- **Nivolumab + Ipilimumab + Chemo:** CheckMate-651 (1L gastric)
- **Pembrolizumab + Trastuzumab deruxtecan:** Ongoing trials
- **Durvalumab combinations:** Investigational
5. **Molecularly Targeted Trials**
- **FGFR2 inhibitors** for FGFR2-amplified gastric cancer
- **MET inhibitors** for MET-amplified tumors
- **NTRK inhibitors** for NTRK fusion-positive tumors
- **BRAF inhibitors** for BRAF V600E
### How to Find Clinical Trials
- **ClinicalTrials.gov** — NCT number searches
- **NCCN.org** — clinical trial finder
- **Cancer.gov** — NCI trial search
- **ASCO.org** — clinical trial resources
- **Patient advocate/ oncology social worker** assistance
---
## 15. POTENTIAL FOR REMISSION OR CURE
### In Stage 4 Gastric Adenocarcinoma, the honest answer is:
**Cure is rare but not impossible.** Complete remission with long-term disease-free survival occurs in a small but meaningful subset of patients.
### Scenarios with Best Chance of Long-Term Remission/Cure:
#### 1. MSI-H/dMMR Tumors + Immunotherapy
- **Most promising scenario for potential cure**
- 25-30% achieve durable complete response lasting >5 years
- Some patients remain disease-free indefinitely
- Pembrolizumab/nivolumab can induce complete, durable remission
- **Annual remission rate:** ~5% per year (responses continue to deepen over time)
#### 2. Oligometastatic Disease + Conversion Surgery
- Highly selected patients with limited metastases (1-2 liver lesions, no peritoneal disease)
- Complete response to systemic therapy + R0 resection
- **5-year survival:** 20-50% in best-selected patients
- Requires young age, good PS, favorable biology
#### 3. Strong Response to Systemic Therapy
- Complete response (CR) rate to first-line chemo + targeted: 10-20%
- CR rate with immunotherapy combinations: 15-25% in PD-L1 high/MSI-H
- Some CR patients remain disease-free for years
#### 4. EBV-Positive Gastric Cancer
- EBV+ gastric cancer (~10% of cases) has high PD-L1 expression
- Particularly responsive to immunotherapy
- CR rates with PD-1 inhibitors: up to 50-80% in EBV+ subset
- **One of the most immunotherapy-responsive subsets**
### Realistic Expectations:
| Scenario | Chance of Long-Term Remission | Chance of True Cure |
|----------|-------------------------------|---------------------|
| Standard chemo alone | <5% | <2% |
| Chemo + trastuzumab (HER2+) | 10-15% | 5-8% |
| Chemo + immunotherapy (CPS≥10) | 15-25% | 10-15% |
| Immunotherapy (MSI-H/dMMR) | 30-40% | 20-30% |
| Immunotherapy (EBV+) | 40-50% | 25-35% |
| Conversion surgery (selected) | 20-40% | 15-25% |
### Important Perspective:
- **"Long-term survivor" in Stage 4:** Patients alive at 5 years
- **Overall 5-year survival for Stage 4 gastric cancer:** ~5-10% (overall), but 20-40% in MSI-H or highly selected conversion surgery patients
- **Every patient is different** — molecular profile, performance status, and response to treatment dramatically influence individual prognosis
---
## 16. QUALITY OF LIFE MANAGEMENT
### Pain Management
- **WHO Analgesic Ladder:**
- Mild pain: NSAIDs, acetaminophen
- Moderate pain: Weak opioids (codeine, tramadol) + NSAIDs
- Severe pain: Strong opioids (morphine, oxycodone, hydromorphone, fentanyl) + NSAIDs
- **Adjuvant analgesics:** Gabapentin/pregabalin (neuropathic pain), duloxetine, corticosteroids
- **Fentanyl patch:** 25-100 mcg/hr every 72 hours for stable pain
- **Patient-controlled analgesia (PCA):** For acute pain exacerbations
- **Radiation:** For bone mets, nerve compression
### Nausea/Vomiting Control
- **5-HT3 antagonists:** Ondansetron 8-16 mg, granisetron, palonosetron
- **NK1 antagonists:** Aprepitant 125 mg Day 1, 80 mg Days 2-3
- **Dexamethasone:** 8-12 mg IV/PO daily
- **Olanzapine:** 5-10 mg PO/IV nightly (especially for refractory nausea)
- **Metoclopramide:** 10-20 mg IV/PO for delayed gastric emptying
- **Prochlorperazine:** 10 mg IV/PO
- **Lorazepam:** 0.5-1 mg PRN for anticipatory nausea
### Dyspnea Management
- Low-dose opioids (morphine 2.5-5 mg PO q4-6h)
- Supplemental oxygen (if hypoxemic)
- Fan to face
- Anxiolytics (lorazepam 0.5-1 mg)
- Treat underlying causes (pleural effusion — thoracentesis, PE — anticoagulation)
### Ascites Management
- **Therapeutic paracentesis:** Large volume, as needed
- **Indwelling catheter (PleurX):** For recurrent malignant ascites
- **Diuretics:** Spironolactone + furosemide (limited efficacy in malignant ascites)
- **Systemic therapy:** May reduce ascites if disease responds
- **Dietary:** Sodium restriction (2 g/day)
### Bowel Obstruction Management
- NGT decompression
- Venting PEG
- Octreotide 100-300 mcg SC TID
- Dexamethasone 4-8 mg/day
- Anticholinergics (glycopyrrolate, scopolamine) for secretions
- Consider palliative stenting if single-point obstruction
### Psychological Support
- **Depression screening:** PHQ-9 every visit
- **Treatment:** SSRIs (sertraline, escitalopram), SNRIs (venlafaxine)
- **Mirtazapine:** 7.5-30 mg nightly (depression + appetite stimulation)
- **Anxiety:** SSRIs, buspirone, short-term benzodiazepines
- **Counseling/therapy:** CBT, supportive therapy
- **Support groups:** Gastric Cancer Foundation, Cancer Support Community
- **Integrative:** Mindfulness, meditation, yoga, art therapy
### Physical Function
- **Exercise:** Light to moderate activity as tolerated
- Walking 15-30 minutes daily
- Resistance training (light weights, 2-3x/week)
- Improves fatigue, muscle mass, mood
- **Physical therapy:** For weakness, neuropathy, post-surgical recovery
- **Occupational therapy:** Adaptive strategies for daily activities
### Social/Financial Support
- **Oncology social worker:** Insurance navigation, financial assistance, transportation
- **Patient assistance programs:** Pharmaceutical manufacturer programs
- **Compassionate use/expanded access:** For unapproved therapies
- **Caregiver support:** Respite care, caregiver counseling
---
## 17. TREATMENT ALGORITHM SUMMARY
```
STAGE 4 GASTRIC ADENOCARCINOMA
├── Molecular Testing (ALL PATIENTS)
│ ├── HER2 (IHC/FISH)
│ ├── PD-L1 CPS
│ ├── MSI/MMR
│ ├── CLDN18.2
│ └── NTRK, BRAF (if available)
│
├── MSI-H/dMMR?
│ ├── YES → Pembrolizumab or Nivolumab monotherapy (POTENTIAL CURE)
│ └── NO → Continue below
│
├── HER2+?
│ ├── YES → Trastuzumab + Chemo (FOLFOX/CAPOX) ± Nivolumab
│ │ 2L: T-DXd (preferred) or Ramucirumab + Paclitaxel
│ └── NO → Continue below
│
├── CLDN18.2+, HER2-?
│ ├── YES → Zolbetuximab + CAPOX/FOLFOX
│ └── NO → Continue below
│
├── First-Line (Unselected / No Targetable Markers)
│ ├── PD-L1 CPS ≥5 → Pembrolizumab or Nivolumab + Chemo (FOLFOX/CAPOX)
│ └── PD-L1 CPS <5 → Chemo alone (FOLFOX/CAPOX) or consider trial
│
├── Second-Line
│ ├── Ramucirumab + Paclitaxel (standard)
│ ├── Ramucirumab + Docetaxel (alternative)
│ └── Immunotherapy if not used in 1L
│
├── Third-Line+
│ ├── Chemo not previously used (paclitaxel, irinotecan, gemcitabine)
│ ├── Immunotherapy if not used
│ └── Clinical trial (CAR-T, bispecifics, ADCs)
│
└── Throughout ALL Stages
├── Early palliative care integration
├── Nutritional support (oral → enteral → parenteral)
├── Symptom management
└── Advance care planning
```
---
## 18. KEY REFERENCES
1. **NCCN Guidelines® for Gastric Cancer** (Version 2.2024/2025)
2. **ESMO Clinical Practice Guidelines for Gastric Cancer** (2024/2025)
3. **AJCC Cancer Staging Manual, 8th Edition**
4. **Bang et al. (2010). TOGA Trial. NEJM.** Trastuzumab in HER2+ gastric cancer
5. **Wagner et al. (2017). FLOT4 Trial. JCO.** Perioperative FLOT
6. **Folprecht et al. (2014). REAL-2. Lancet Oncol.** FOLFIRI vs FOLFOX
7. **Cunningham et al. (2013). RAINBOW. Lancet.** Ramucirumab + paclitaxel
8. **Fuchs et al. (2014). REGARD. JCO.** Ramucirumab monotherapy
9. **Fuchs et al. (2021). CheckMate-649. NEJM.** Nivolumab + chemo
10. **Shitara et al. (2024). KEYNOTE-859. Lancet.** Pembrolizumab + chemo (CAPOX/SOX)
11. **Boku et al. (2024). SPOTLIGHT. NEJM.** Zolbetuximab + chemo
12. **Bang et al. (2024). GLOW. Lancet.** Zolbetuximab + chemo
13. **Shitara et al. (2022). DESTINY-Gastric01. Lancet Oncol.** T-DXd
14. **Shitara et al. (2024). DESTINY-Gastric02.** T-DXd vs Paclitaxel
15. **Keynote-158. NEJM.** Pembrolizumab in MSI-H solid tumors
16. **Temel et al. (2010). NEJM.** Early palliative care
17. **ESMO/ESPEN Guidelines on Nutrition in Cancer** (2022/2024)
18. **ASCO Guidelines on Palliative Care Integration** (2017, reaffirmed)
19. **CAR-T Clinical Trial Data (AP0101/CT041)** — Nature Medicine, Blood, JCO (2023-2025)
20. **ESMO 2024/2025 Guidelines Updates**
---
*Document compiled: May 7, 2026*
*This document is for informational purposes and should not replace professional medical advice. Treatment decisions should be made in consultation with a qualified oncology team.*